Approximately 30% of individuals receive a clinical diagnosis of RSTS based on phenotypic presentation with no identifiable pathogenic variant in CREBBP or EP300 found (Bartsch et al., 2005; Stevens, 2019). This evidence concerns the gene EP300 and Rubinstein-Taybi syndrome.